This, in addition to the facts that JAG1 is often upregulated in tumor cells (although generally not mutated in cancer), and that ligand-induced activation is required even in the presence of some Notch receptor mutations, makes it a particularly attractive target for therapy (143). Here, JAG1 is linked to neoplasm.